Hydroxy-PEG5-Boc

CAS No. 850090-09-4

Hydroxy-PEG5-Boc( —— )

Catalog No. M24846 CAS No. 850090-09-4

Hydroxy-PEG6-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG 26 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Hydroxy-PEG5-Boc
  • Note
    Research use only, not for human use.
  • Brief Description
    Hydroxy-PEG6-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • Description
    Hydroxy-PEG6-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • In Vitro
    PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    PROTACs
  • Target
    PROTAC
  • Recptor
    PEGs
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    850090-09-4
  • Formula Weight
    366.45
  • Molecular Formula
    C17H34O8
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(OC(C)(C)C)CCOCCOCCOCCOCCOCCO
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562
molnova catalog
related products
  • QCA570

    QCA570 is a novel, highly potent efficacious BET degrader (PROTAC); effectively induces degradation of BET proteins and inhibits cell growth in human acute leukemia cell lines at pM level.

  • dBET57

    dBET57 is a novel BRD4 heterobifunctional small-molecule ligand (PROTAC), exhibits significant and selective degradation of BRD4 BD1 (DC50/5h=500 nM).

  • PAC

    PAC1 (Compound PAC1) is a novel PROTAC antibody conjugate, more potent estrogen receptor-alpha (ERα) degrader compared to PROTAC without antibody conjugation.